TransCode's TTX-MC138 Enters Phase 2a Trial in Quantum Leap PRE-I-SPY Platform
ByAinvest
Friday, Dec 12, 2025 9:30 am ET1min read
RNAZ--
TransCode Therapeutics and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TTX-MC138 in a Phase 2a trial. TTX-MC138, a therapeutic candidate designed to inhibit microRNA-10b, a biomarker linked to metastatic cancers, achieved its primary safety endpoint and established a recommended Phase 2 dose in its Phase 1a trial. The Phase 2a study will enroll up to 45 patients with colorectal cancer who have completed standard therapy but remain ctDNA-positive, indicating minimal residual disease. The study aims to evaluate the biological and clinical activity of TTX-MC138 in the MRD setting.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet